Oppenheimer Maintains Outperform on BrainsWay, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on BrainsWay (NASDAQ:BWAY) and raises the price target from $10 to $11.
May 09, 2024 | 4:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Steven Lichtman reaffirmed an Outperform rating on BrainsWay and increased the price target from $10 to $11.
The increase in price target by a reputable analyst suggests a positive outlook on BrainsWay's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100